Defibrotide in the prevention and treatment of veno‐occlusive disease in autologous and allogeneic stem cell transplantation in children
Pediatric Blood & Cancer2008Vol. 50(4), pp. 831–832
Citations Over TimeTop 10% of 2008 papers
Abstract
VOD incidence and severity was reduced in the defibrotide group which suggests that defibrotide might be effective in preventing and treating VOD. Sufficiently powered randomised trials are now required to definitively test the role of defibrotide in this setting.
Related Papers
- → Safety and efficacy of defibrotide for the treatment of severe hepatic veno-occlusive disease(2012)47 cited
- → Pooled Treatment Analysis of Pediatric Patients with Defibrotide for Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome and Multi-Organ Dysfunction Following Hematopoietic Stem Cell Transplant(2016)2 cited
- → Defibrotide for the Treatment of Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome with/without Multi-Organ Dysfunction Following Chemotherapy: Subset Analysis Results from an Ongoing Expanded Access Program(2016)
- → Timing of Initiation of Defibrotide Post-Diagnosis of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) After Hematopoietic Stem Cell Transplantation (HSCT): Final Data from an Expanded-Access Protocol(2017)
- → Day+100 Survival and Safety Results from a Defibrotide Expanded-Access Program for Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS): Final Results(2017)